EGFR and neoplasm: Previous studies have suggested that patients with high PD-L1 expression are more likely to have primary resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) treatment, which may be related to the suppressive tumor microenvironment (30–32).